Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SILA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Securities Litigation (new) — Two shareholder lawsuits seek to enjoin the merger unless additional disclosures are made, with 15 additional demand letters alleging proxy deficiencies
Sila Realty Trust faces shareholder lawsuits over merger proxy disclosures
Filed June 17, 2026 · Period ending June 17, 2026 · ~1 min read
Key Changes
-
high
Two lawsuits and 15 demand letters allege SILA's merger proxy omits material information; company denies claims but filed supplemental disclosures to avoid litigation delays ahead of June 26 shareholder vote
Item 8.01 — Other Events verify on EDGAR → -
medium
Supplemental proxy reveals 81 potential buyers contacted, 31 signed NDAs without 'don't ask, don't waive' standstill provisions; Blue Owl's winning $30.38/share bid included no management equity rollovers
Item 8.01 — Other Events verify on EDGAR → -
medium
BofA Securities' fairness analysis used 2026E EV/EBITDA multiples of 11.0x-15.3x for healthcare REITs and DCF discount rates of 7.8%-8.7% with exit multiples of 12.0x-15.0x EBITDA
Item 8.01 — Other Events verify on EDGAR →
Summary
Sila Realty Trust disclosed that two shareholder lawsuits and fifteen demand letters challenge the adequacy of its merger proxy disclosures ahead of the June 26 special meeting to vote on Blue Owl's $30.38 per share acquisition. The complaints seek to block the transaction unless additional information is provided or to recover damages if the deal closes.
While SILA denies the allegations have merit, the company filed supplemental proxy materials to avoid litigation-related delays to the merger timeline. The supplemental disclosures provide transparency into the sale process and valuation work that shareholders will evaluate when voting.
SILA contacted 81 potential buyers, with 31 signing NDAs that contained no 'don't ask, don't waive' standstill provisions that could have chilled competing bids. Blue Owl's winning proposal included no management equity rollovers or post-closing employment arrangements for executives or directors. BofA Securities' fairness opinion relied on healthcare REIT trading multiples of 11.0x-15.3x 2026E EV/EBITDA and DCF analysis using 7.8%-8.7% discount rates with 12.0x-15.0x EBITDA exit multiples. The litigation creates uncertainty around deal timing and potential settlement costs, though SILA's voluntary supplemental disclosures may reduce the risk of an injunction blocking the shareholder vote.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Between January 20, 2026 and mid-March 2026, BofA Securities contacted 81 potentially interested third-party buyers. BofA Securities shared the form of nondisclosure agreement with each potential buyer that expressed an interest in receiving more information regarding a potential transaction with the Company, which non-disclosure agreement contained, among other provisions, a standstill provision, an employee non-solicitation provision, and a 24-month term. From January 20, 2026 through March 13, 2026, the Company negotiated nondisclosure agreements with approximately 43 third parties and entered into nondisclosure agreements with 31 third parties. None of the nondisclosure agreements contained ‘don't ask, don't waive’ provisions.
SILA disclosed that 81 potential buyers were contacted, 31 signed NDAs, and none of the NDAs contained 'don't ask, don't waive' standstill provisions. The supplement also clarifies that none of the preliminary or final proposals from bidders included post-closing employment arrangements or equity participation for board members or executives.
Added in current filing · verify on EDGAR →
Later in the evening on April 15, 2026, Blue Owl submitted a final letter of interest indicating, among other items, a proposal to acquire all outstanding Company Common Stock for $30.38 per share in cash (the “Blue Owl Final Proposal”). The Blue Owl Final Proposal provided that the Company could continue the payment of its regular quarterly dividends, not to exceed $0.40 per share. Additionally, Blue Owl requested an exclusivity period with the Company for a period of 10 days. The Blue Owl Final Proposal did not include any discussions or proposals regarding post-closing employment arrangements or the participation in the equity of the surviving company for any members of the Board or the Company’s executive officers.
SILA clarified that Blue Owl's final proposal was $30.38 per share and that Consortium A, despite indicating it would submit a proposal by April 20, 2026, never submitted a final proposal. The supplement confirms no management equity rollovers or employment arrangements were part of any bid.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 29, 2026 · How we verify